In contrast, CD3+CD4+ T-lymphocytes, the most abundant lymphocytic infiltrating population, and CD3+CD8+ T-lymphocytes did not change between the different group of treatments (Figure S6), while B-lymphocytes were very low (always < 1.5% compared to total CD3+ T-lymphocytes) within tumor mass (data not shown). This evidence concerns the gene CD4 and neoplasm.